These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35007784)

  • 1. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors.
    Lee JH; Song J; Kim IG; You G; Kim H; Ahn JH; Mok H
    Acta Biomater; 2022 Mar; 141():354-363. PubMed ID: 35007784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.
    Lin W; Li C; Xu N; Watanabe M; Xue R; Xu A; Araki M; Sun R; Liu C; Nasu Y; Huang P
    Int J Nanomedicine; 2021; 16():2775-2787. PubMed ID: 33880023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity.
    Jiang X; Liu J; Lee MJ; Peng C; Luo T; Tillman L; Weichselbaum RR; Lin W
    Biomaterials; 2023 Nov; 302():122334. PubMed ID: 37776767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes.
    Wang D; Wan Z; Yang Q; Chen J; Liu Y; Lu F; Tang J
    Drug Deliv; 2022 Dec; 29(1):702-713. PubMed ID: 35236203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment.
    Wang X; Zhang Y; Mu X; Tu CR; Chung Y; Tsao SW; Chan GC; Leung WH; Lau YL; Liu Y; Tu W
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient Delivery of Tyrosinase Related Protein-2 (TRP2) Peptides to Lymph Nodes using Serum-Derived Exosomes.
    Park O; Choi ES; Yu G; Kim JY; Kang YY; Jung H; Mok H
    Macromol Biosci; 2018 Dec; 18(12):e1800301. PubMed ID: 30407735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
    Thauvin C; Widmer J; Mottas I; Hocevar S; Allémann E; Bourquin C; Delie F
    Eur J Pharm Biopharm; 2019 Jun; 139():253-261. PubMed ID: 30981947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
    Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
    Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
    Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
    J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-Loaded Squalene Emulsion.
    Zhang Z; Kuo JC; Zhang C; Huang Y; Lee RJ
    J Pharm Sci; 2022 Nov; 111(11):3038-3046. PubMed ID: 35697319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
    Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
    J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
    Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
    Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
    Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
    Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
    Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboxymethylated Alginate-Resiquimod Micelles Reverse the Immunosuppressive Tumor Microenvironment and Synergistically Enhance the Chemotherapy and Immunotherapy for Gastric Cancer.
    Chen J; Liu X; Zhao S; Chen H; Lu T; Wang J; Han J; Wu W; Shen X; Li C
    ACS Appl Mater Interfaces; 2023 Aug; 15(30):35999-36012. PubMed ID: 37477904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.